TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 171 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $9,412,515 | +6.9% | 418,520 | 0.0% | 0.36% | +7.8% |
| Q4 2022 | $8,801,476 | +44.2% | 418,520 | +69.0% | 0.33% | +32.8% |
| Q3 2022 | $6,103,000 | +1.7% | 247,678 | 0.0% | 0.25% | +5.9% |
| Q2 2022 | $6,001,000 | -6.0% | 247,678 | 0.0% | 0.24% | +5.4% |
| Q1 2022 | $6,383,000 | -3.4% | 247,678 | +16.4% | 0.22% | +5.2% |
| Q4 2021 | $6,607,000 | +28.0% | 212,869 | 0.0% | 0.21% | +28.3% |
| Q3 2021 | $5,162,000 | +66.2% | 212,869 | 0.0% | 0.17% | +64.4% |
| Q2 2021 | $3,106,000 | -41.6% | 212,869 | 0.0% | 0.10% | -44.8% |
| Q1 2021 | $5,315,000 | – | 212,869 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |